MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze EW →
    • FindStock Picks / Stock Screener
    • Value · EWIntrinsic Value Calculator
    • Invest · EWInvestment Case
    • Hold · EW5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
EW stock logo

EW

Edwards Lifesciences Corporation

$107.15
1.35
 (1.28%)
Exchange:  NYSE
Market Cap:  61.611B
Shares Outstanding:  584.8M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – DevicesView industry performance
   
CEO:  Bernard J. Zovighian
Full Time Employees:  16000
Address: 
One Edwards Way
Irvine
CA
92614
US
Website:  https://www.edwards.com
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients’ cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
EWEW logoEWEdwards Lifesciences Corporation61.6B60.535.59.3%
BSBSX logoBSXBoston Scientific Corporation64.3B18.714.010.5%
GEGEHC logoGEHCGE HealthCare Technologies Inc.37.5B17.516.57.8%
DXDXCM logoDXCMDexCom, Inc.31.1B32.230.924.0%
PHPHG logoPHGKoninklijke Philips N.V.29.5B27.216.66.6%
ZBZBH logoZBHZimmer Biomet Holdings, Inc.19.5B26.012.15.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/07/23 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue5,010,0005,439,5006,067,600
Gross Profit3,972,7004,322,0004,740,700
EBITDA1,534,9001,723,1001,429,500
Operating Income1,427,3001,378,7001,636,200
Net Income1,402,4004,174,6001,073,500

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets9,363,20013,055,30013,697,200
Total Liabilities2,643,8002,992,4003,359,600
Total Stockholders Equity6,650,0009,998,40010,337,600
Total Debt685,100700,000107,100
Cash and Cash Equivalents1,132,3003,045,2002,938,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow895,800542,3001,595,200
Capital Expenditure-266,300-252,400-260,200
Free Cash Flow629,500289,9001,335,000
Net Income1,402,4004,169,7001,069,400
Net Change in Cash375,4001,910,800-119,300

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)9,610,317.625Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)10,053,786.903Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)9,847,683.333Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)3,262,661.919Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)3,438,149.751Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)3,356,592.538Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)2,664,148.108Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)2,825,161.096Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)2,750,331.004Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)3,008,132.594Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)3,146,943.239Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)3,082,430.609Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)4.700Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)4.820Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)4.550Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)12Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)3Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
5.44B  ?P/S
 (TTM)
: 
9.23
?Net Income
 (TTM)
: 
874.6M  ?P/E
 (TTM)
: 
60.54
?Enterprise Value
 (TTM)
: 
59.205B  ?EV/FCF
 (TTM)
: 
41.57
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
9.69%  ?ROIC
 (TTM)
: 
9.33%
?Net Debt
 (TTM)
: 
-3.279B  ?Debt/Equity
 (TTM)
: 
0.06
?P/B
 (TTM)
: 
5.69  ?Current Ratio
 (TTM)
: 
4.6

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
35.48Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates EW intrinsic value between $54.33 – $62.80 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate EW Intrinsic Value

Common questions about EW valuation

Is Edwards Lifesciences Corporation (EW) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Edwards Lifesciences Corporation (EW) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is EW a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EW trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is EW’s P/E ratio?

You can see EW’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for EW?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is EW a good long-term investment?

Whether EW fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Edwards Lifesciences Corporation

  • Edwards Lifesciences Corporation intrinsic value calculatorEstimate what the business is worth
  • Edwards Lifesciences Corporation 5-year outlookWhat has to go right, and what could go wrong
EW

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.28
MarketSnap

Trading Metrics:

Open: 106.11   Previous Close: 105.8
Day Low: 106.01   Day High: 107.69
Year Low: 74.66   Year High: 107.69
Price Avg 50: 90.08   Price Avg 200: 86.21
Volume: 3.822M   Average Volume: 4.081M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs
05-11-2026 09:50
Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs
Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript
04-11-2026 22:24
Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript
CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
02-11-2026 13:25
CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics
30-10-2026 10:16
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Is This the Right Time to Hold EW Stock in Your Portfolio?
22-10-2026 09:51
Is This the Right Time to Hold EW Stock in Your Portfolio?
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
07-10-2026 06:00
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze EW →
    • FindStock Picks / Stock Screener
    • Value · EWIntrinsic Value Calculator
    • Invest · EWInvestment Case
    • Hold · EW5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.